The European Medicines Agency confirms that finasteride poses a risk for suicidal ideation and urges healthcare professionals to be alert for mood changes in treated patients.

Finasteride is sold in 1 mg tablets under brand names such as Propecia. Meanwhile, 5 mg tablets are used to treat prostate enlargement that can cause problems urinating.

Finasteride is most commonly used for hair loss at a daily dosage of 1mg. The majority of hair loss medications containing finasteride use this dose, including the original 1mg Propecia tablets.

Sandoz demonstrated resilience in Q1 2025 with a 3% rise in net sales, primarily fueled by a 6% volume growth. However, price erosion offset some gains, resulting in a net positive performance.

Introduction & Market Context Sandoz Group AG (SIX: SDZ) presented its first quarter 2025 sales update on April 30, revealing 3% net sales growth in constant currency terms, primarily driven by strong ...

Sandoz reports Q1 2025 net sales in line with company expectations; full-year guidance confirmed Published Apr 30, 2025 1:00am EDT ...

Sandoz confirmed its full-year 2025 guidance with the following key metrics: The company expects mid-single digit net sales growth in constant currencies and a core EBITDA margin of around 21%.

Sandoz reports Q1 2025 net sales in line with company expectations; full-year guidance confirmed Provided by GlobeNewswire Apr 29, 2025, 10:00:00 PM ...

For decades, millions of men around the world have turned to a drug — finasteride, or Propecia, its most well-known brand name — to slow hair loss. But an increasing number of experts are ...

Sandoz has agreed to an upfront licensing fee of US$3M (approx. A$4.8M [1]) for the exclusive commercial rights to the CBD product for insomnia in Australia. Avecho will continue to fund and ...

Basel, February 24, 2025 - Sandoz (SIX:SDZ/OTCQX:SDZNY), the global leader in generic and biosimilar medicines, announces the launch of Pyzchiva®* (ustekinumab-ttwe) in the US.

Pyzchiva® is a key biosimilar value driver for Sandoz, contributing to the company’s overall growth strategy. The company ranks number one in biosimilars globally and across key markets in Europe.